Supplier of Hormonal and Specialty Medications

The contract entails the supply of low-volume, high-complexity pharmaceuticals, specifically focusing on hormonal therapies such as estradiol and testosterone, as well as controlled substances intended for specialized research purposes. Managed by the FDA Office of Acquisition and Grant Services within the Department of Health and Human Services, this subcontract aims to secure a reliable source for these critical medications, which are likely integral to advanced medical or scientific investigations. Issued in early May 2026, the solicitation calls for responses by mid-May 2026, emphasizing the need for timely engagement from qualified suppliers. Although detailed location information is not specified, the contract falls under the NAICS code 325412, which relates to pharmaceutical preparation manufacturing. While there are no set-aside provisions indicated, the opportunity is focused on entities capable of meeting stringent demands associated with the complexity and regulatory constraints of hormonal and controlled substances procurement for specialized research applications.